Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
University Health Network, Toronto
Endeavor Biomedicines, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
Genmab
Nuvectis Pharma, Inc.
A2 Biotherapeutics Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
University Hospital, Lille
Royal Marsden NHS Foundation Trust
PrECOG, LLC.
Takeda
IDEAYA Biosciences
Lumicell, Inc.
Perspective Therapeutics
Seagen Inc.
Dana-Farber Cancer Institute
Novartis
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
VM Oncology, LLC
Dana-Farber Cancer Institute
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Brigham and Women's Hospital
Tango Therapeutics, Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Ipsen
Brigham and Women's Hospital
Vivace Therapeutics, Inc
Incyte Corporation
Actym Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Merck Sharp & Dohme LLC
Novartis
TCR2 Therapeutics
TCR2 Therapeutics
National Cancer Center, China
Incyte Corporation
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
University of Pittsburgh